The Technology
Multiple myeloma (MM) is a progressive malignancy of plasma cells with 5-year relative survival rates of 55%. Bortezomib (Velcade®) is the standard of care, yet some patients fail to respond to such therapy for reasons associated with the drug characterization. The development of new bortezomib-based drugs with specific targeting capabilities and improved therapeutic activity is therefore required. ATBL – a nanoparticle that specifically targets MM in their niche. The nanoparticle contains surface conjugated AMD3100 (Plerixafor®) with an internal core of bortezomib. The efficacy of ATBL has been tested in vivo in mice bearing MM cells. Tumor burden was assessed by bioluminescent representing MM cells in mice. Study results prove ATBL is superior to bortezomib given as a free drug or as a non-targeted nanoparticle.
Advantages
- Long pharmacokinetic activity.
- Companion diagnostic potential.
- Targeting capability specifically to MM cells.
- Reduced side effects and improved outcome.
- Reduced number of administrations.
- Reduced acquired resistance mediated by host effects.
Applications and Opportunities
- Targeted MM Treatment
- Targeted therapy for other Bone-marrow pathologies
Business Development Contacts